Ema starts modern vaccine evaluation for age group 6-11

The EMA has started the evaluation of the application submitted by Moderna to obtain the green light for the use of its anti-Covid vaccine Spikevax for children between the ages of 6 and 11.

Normally, the European Medicines Agency completes its evaluation within two months of submitting the application but, as Ema reminds itself, the timing of the procedure always depends on the data presented by those who apply for authorization.

And from the eventuality that the acquisition of further information is needed.

Once made known, the eventual green light of Ema on the use of the Moderna vaccine for children will have to receive the definitive green light from the European Commission, the institution which is responsible for making the final decision.